EMulate Therapeutics, Inc. (EMTX)

EMulate Therapeutics was planning to go public, but the IPO was withdrawn on Jul 31, 2024.

IPO Price Range

$4.00 - $6.00

Shares Offered

2,300,000

Deal Size

$11.50M

EMulate Therapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year Ending	TTM	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020
Revenue	0.26	0.24	0.11
Revenue Growth (YoY)	-	113.27%	-
Gross Profit	0.26	0.24	0.11
Selling, General & Admin	-	10.03	8.69
Research & Development	-	1.54	2.06
Operating Expenses	-	11.57	10.75
Operating Income	-15.97	-11.33	-10.64
Interest Expense / Income	3.36	2.99	1.52
Other Expense / Income	8.69	7.77	-14.78
Pretax Income	-28.02	-22.09	3.46
Net Income	-28.02	-22.09	2.62
Net Income Common	-28.02	-22.09	3.46
Free Cash Flow	-3.88	-3.32	-4.02
Gross Margin	100.00%	100.00%	100.00%
Operating Margin	-6264.31%	-4700.41%	-9412.39%
Profit Margin	-10989.41%	-9166.80%	3059.29%
Free Cash Flow Margin	-1520.39%	-1378.42%	-3555.75%
EBITDA	-23.9	-18.06	4.74
EBITDA Margin	-9370.59%	-7491.70%	4190.27%
Depreciation & Amortization	0.77	1.04	0.59
EBIT	-24.66	-19.1	4.14
EBIT Margin	-9670.59%	-7924.90%	3664.60%

Source: IPO financials are sourced from S-1 and S-1/A filings submitted to the Securities and Exchange Commission (SEC).